Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VaxInnate Inc.

This article was originally published in Start Up

Executive Summary

VaxInnate is linking the innate and adaptive immune response to get the optimal action from a vaccine. Work done in the Yale labs of company founders demonstrated that fusing a polypeptide ligand specific for a TLR to an antigen of interest generates a vaccine that may prove more potent and selective than the antigen alone. It also eliminates the need for formulating the vaccine in complex adjuvants-and it opens the door to production using simplified recombinant methods.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts